Last reviewed · How we verify
Tezepelumab (AI)
Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma.
Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma. Used for Severe asthma.
At a glance
| Generic name | Tezepelumab (AI) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-33 antagonist |
| Target | IL-33 |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
IL-33 is a cytokine that plays a key role in the development of asthma by promoting the activation and differentiation of immune cells. By blocking IL-33, tezepelumab reduces inflammation and airway hyperresponsiveness in patients with asthma.
Approved indications
- Severe asthma
Common side effects
- Headache
- Nausea
- Injection site reaction
Key clinical trials
- Tezepelumab Home Use Study (PHASE3)
- A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tezepelumab (AI) CI brief — competitive landscape report
- Tezepelumab (AI) updates RSS · CI watch RSS
- AstraZeneca portfolio CI